Figure 3.
mPPGL patients treated with 177Lu the mPFS was nr (right).
The mOS of this population was 143.5 months (95% CI 143.5-146.2 months) (left).
CI, confidence interval; mOS, median overall survival; mPFS, median progression-free survival; mPPGL, metastatic pheochromocytoma and paraganglioma; nr, not reached.